Key takeaways
- Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, whose first four amino acids are the sequence of tuftsin; Semax is Met-Glu-His-Phe-Pro-Gly-Pro, which FDA staff describe as an analogue of the ACTH 4–10 fragment.
- Of 68 PubMed records on Selank, 50 involve rats or mice; of 210 on Semax, 153 do (one search method for both: title, abstract or subject heading, 18 Nov 2026).
- Both have few, mostly small human studies, none registered on ClinicalTrials.gov. One 2020 study gave Semax, Selank or placebo to 52 healthy people and recorded brain connectivity on fMRI.
- Their US paths split in 2026: against FDA staff’s recommendation, an FDA advisory committee voted in favour of listing Semax for compounding, and HHS named it in a draft, non-binding policy; Selank was on neither the committee’s agenda nor the policy.
- Neither is named on WADA’s 2026 or 2027 List, and whether class S0 applies to either is unresolved.
01Selank vs Semax in one table
The same questions for both, dated 18 November 2026.
| Question | Selank | Semax |
|---|---|---|
| What it is | Seven amino acids, Thr-Lys-Pro-Arg-Pro-Gly-Pro; 751.9 g/mol; also called TP-7 | Seven amino acids, Met-Glu-His-Phe-Pro-Gly-Pro; 813.9 g/mol; synthetic |
| Parent molecule | Its first four amino acids are the sequence of tuftsin | FDA staff: an analogue of ACTH 4–10, a fragment of the hormone ACTH |
| Main models (tier) | Rats and mice, 50 records; cell studies (T3, T4) | Rats and mice, 153 records (T3) |
| Human studies | Five small studies, all sharing one author; graded T2 here because their abstracts do not describe how participants were assigned (PubMed indexes two as randomised trials); none registered on ClinicalTrials.gov | Eight references reviewed by FDA staff, few and mostly small; graded T2 here because none we could read describes random assignment; none registered on ClinicalTrials.gov |
| Independent verdict | A 2021 US review: phenibut and Selank are “poorly studied Russian drugs” | FDA staff, 2026: “insufficient evidence” of effectiveness for the three uses they evaluated |
| United States (Nov 2026) | Drugs@FDA lists no product. Withdrawn Category 2 nomination; not on the July 2026 committee agenda or in HHS’s October 2026 policy | Drugs@FDA lists no product. FDA staff recommended against listing it for compounding; the advisory committee voted in favour (Jul 2026); named in HHS’s draft, non-binding policy (Oct 2026) |
| United Kingdom | Not confirmed from a primary record | No result on the emc medicines database |
| Australia | Not named in the Poisons Standard October 2026 | Not named in the Poisons Standard October 2026 |
| WADA | Not named on the 2026 or 2027 List; check with your anti-doping body | Not named on the 2026 or 2027 List; check with your anti-doping body |
02Are Selank and Semax the same molecule?
No. Both are chains of seven amino acids, and the last three are the same, Pro-Gly-Pro; the first four all differ. Selank’s first four amino acids are the sequence of tuftsin, and Russian research papers describe it as a tuftsin analogue. FDA staff describe Semax as a synthetic analogue of ACTH 4–10, a fragment of adrenocorticotropic hormone. Citing earlier research, they write that Semax lacks the hormone’s effect on the adrenal glands, and that its Pro-Gly-Pro ending is thought to make it more resistant to breakdown by enzymes.
How a lab tells them apart. By mass: 751.9 g/mol for Selank, 813.9 g/mol for Semax. Researchers at Sciensano in Brussels identified both in two unknown preparations seized in 2017 and 2018, then built a mass spectrometry screen for such peptides. A purity percentage cannot show which peptide a vial holds: see mass spectrometry explained and how to read a COA.
03How have Selank and Semax been studied, and in what models?
Mostly in rats and mice, for both. Animal and cell findings are not evidence of an effect in people.
Selank. Of the 68 PubMed records with Selank in the title or abstract (18 November 2026), 64 are from Russian journals or research groups, and 50 involve rats or mice (by title, abstract or subject heading, the method used for Semax below). These laboratories propose a mechanism involving the brain’s GABA-A receptor system, from rat-tissue and cell studies (T4).
Semax. Of the 210 PubMed records with Semax in the title or abstract, 153 involve rats or mice and 89 are in Russian. FDA staff describe rodent studies in several areas, with Semax acting “through poorly understood mechanisms of action”.
Side by side. Eleven PubMed records mention both. One is a 2001 laboratory study in which both inhibited enzymes in human serum that break down enkephalins and other regulatory peptides: a test-tube finding (T4). Both peptides are covered on Semax and Selank research.
04What human studies of Selank and Semax exist?
Few, mostly small ones, and none registered on ClinicalTrials.gov (searched 18 November 2026). We report how the studies were designed, not what their authors concluded.
Selank. We found five studies in PubMed that gave Selank to people, from 2008 to 2020; the largest had 70 patients. Four were in patients, three of them comparing Selank with a benzodiazepine or adding it to one. All five list the same author, N. F. Myasoedov, only one abstract describes a placebo group, and we found no human study of Selank from another research group. Details: Selank research guide.
Semax. FDA staff counted eight references that gave Semax to people: 33 to 47 healthy adults, 69 adults with medical conditions and 451 children. Three were meeting abstracts, and in several Semax was given with other treatments, “making it difficult to determine the contribution of semax to any effects seen”. For the three uses they could evaluate, FDA staff found “insufficient evidence” of effectiveness, from only two references with insufficient detail on how the studies were run. Details: Semax research guide.
The one study that gave both. In 2020, Panikratova and colleagues gave Semax, Selank or a placebo to 52 healthy participants and recorded resting brain connectivity on fMRI, before and twice in the 20 minutes after. Of the 11 PubMed records that mention both peptides, it is the only one we found that gave either to people. It measured brain imaging, not a health outcome.
05What have regulators said about Selank and Semax safety?
Semax. Briefing FDA’s compounding advisory committee in July 2026, FDA staff concluded there is “insufficient clinical information to characterize the safety profile” of Semax; most of the human references “did not discuss safety”. FDA’s adverse-event database held one report through 3 December 2025: a consumer described eye pain and burning after using a Semax product bought online, and a hospitalisation, with the pain unresolved a year later. FDA staff also flagged a possible bleeding risk and a mouse finding on dopamine release, a response “typically induced by drugs of abuse”. HHS read the record differently: its 2026 policy appendix calls these concerns “mechanistic rather than observed”, saying the human record “covers several hundred subjects with no reported adverse outcome”.
Selank. The FDA statement we found is a short entry on its compounding page: drugs compounded with selank acetate “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities”, and FDA “lacks important information regarding any safety issues raised by selank acetate administered to humans”. Immunogenicity is the tendency to provoke an immune response. The page’s Semax entry carries the same immunogenicity wording and adds that FDA “lacks sufficient information to know whether the drug would cause harm if administered to humans”. How to weigh statements like these: peptide side effects, documented and unknown.
06Where do Selank and Semax stand legally?
United States. Semax sat in FDA’s compounding Category 2 from 29 September 2023 to 22 April 2026. FDA’s drug centre recommended against listing it for compounding; in July 2026 the advisory committee voted in favour. HHS then named Semax among six peptides in a policy saying it does not intend to take enforcement action when licensed pharmacies and physicians compound them under conditions; the Federal Register notice of 30 October 2026 calls the policy a draft that “is not binding”. Selank took a different path: FDA lists “Selank acetate (TP-7)” among withdrawn Category 2 nominations, with no date, and it was neither on the July 2026 agenda nor in the HHS policy. Background: the July 2026 vote and the HHS policy.
UK, Australia and Russia. The emc medicines database returned no result for Semax on 18 November 2026, and we could not confirm Selank’s UK status from a primary record. Neither is named in Australia’s Poisons Standard October 2026; scheduling is not approval. FDA staff wrote that Semax “is a registered drug in Russia”, citing Russia’s state register of medicines, accessed in December 2025. We could not open that register to confirm it, or to check Selank’s status there. Research-grade Semax is not that registered medicine. More: UK and Australia.
Sport. Neither is named on WADA’s 2026 or 2027 Prohibited List. Class S0 covers any pharmacological substance not addressed elsewhere “and with no current approval by any governmental regulatory health authority for human therapeutic use”. Whether S0 reaches either depends on approval status abroad that we could not verify, and anti-doping organisations decide: peptides and anti-doping.
07What we don’t know about Selank and Semax
- Whether either peptide does anything in people. Neither has a placebo-controlled trial registered on ClinicalTrials.gov.
- How the two compare in people. The one study that gave both recorded brain imaging in 52 healthy volunteers.
- Their safety over months or years. FDA staff found “insufficient clinical information to characterize the safety profile” of Semax and no human pharmacokinetic study of it, and FDA lacks important safety information on Selank.
- Their status in Russia, and Selank’s status in the UK.
- What a vial sold under either name contains. Only an identity result on that lot’s lab report can show it.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.